D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism
D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism
复制标题
DOI：
10.1016/j.nbd.2013.10.029
复制
发表时间：
2014-03-01
影响因子：
6.1
通讯作者：
Ghorayeb, Imad
中科院分区：
文献类型：
--
作者：
Hyacinthe, Carole;Barraud, Quentin;Ghorayeb, Imad
白天过度嗜睡（EDS）和快速眼动（REM）睡眠失调都是帕金森病（PD）非运动症状的一部分，可能使多巴胺替代治疗复杂化。我们在这里报告，多巴胺受体激动剂作用差异1-甲基-4-苯基-1，2，3，6-四氢吡啶猕猴的睡眠结构。连续睡眠和清醒脑电图监测显示，选择性多巴胺D2受体激动剂喹吡罗对EDS没有影响，而选择性多巴胺D1受体激动剂SKF 38393有效地减轻EDS和恢复REM睡眠到基线值。目前的研究结果质疑放弃D1受体激动剂治疗PD的相关性，因为它实际上可能改善睡眠相关疾病。(C)版权所有© 2013 Elsevier Inc.
Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy. We report here that dopamine agonists act differentially on sleep architecture in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque monkey. Continuous sleep and wake electroencephalographic monitoring revealed no effect of the selective dopamine D2 receptor agonist quinpirole on EDS, whereas the selective dopamine D1 receptor agonist SKF38393 efficiently alleviated EDS and restored REM sleep to baseline values. The present results question the relevance of abandoning D1 receptor agonist treatment in PD as it might actually improve sleep-related disorders. (C) 2013 Elsevier Inc All rights reserved.